key: cord-1018749-rcows2f0 authors: Pérez-García, Felipe; Martin-Vicente, María; Rojas-García, Rosa Lía; Castilla-García, Lucia; Muñoz-Gomez, María José; Hervás Fernández, Irene; González Ventosa, Victoria; Vidal-Alcántara, Erick Joan; Cuadros-González, Juan; Bermejo-Martin, Jesús F; Resino, Salvador; Martínez, Isidoro title: High SARS-CoV-2 viral load and low CCL5 expression levels in the upper respiratory tract are associated with COVID-19 severity date: 2021-12-15 journal: J Infect Dis DOI: 10.1093/infdis/jiab604 sha: c9d4fb50b0461ff14a3c2e100b7a5594812b4580 doc_id: 1018749 cord_uid: rcows2f0 Mucosal immune response in the upper respiratory tract is crucial for the initial control of viral replication, the clearance of SARS-CoV-2, and the progression of the coronavirus disease 2019 (COVID-19). We analyzed the SARS-CoV-2 RNA load and the expression of selected immune genes in the upper respiratory tract (nasopharynx) of 255 SARS-CoV-2 infected patients and evaluated their association with severe COVID-19. SARS-CoV-2 replication in the nasopharyngeal mucosa induces the expression of several innate immune genes. High SARS-CoV-2 viral load and low CCL5 expression levels were associated with ICU admission or death, although CCL5 was the best predictor of COVID-19 severity. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection causes the coronavirus disease 2019 (COVID-19), a disease with high mortality and morbidity rates worldwide. Clinical manifestations range from mild symptoms to pneumonia and severe acute respiratory syndrome. The proinflammatory response and viral replication are closely related to the severity of the disease and risk of death [1] . SARS-CoV-2 infection initiates in the upper respiratory tract, mainly in nasal epithelial cells, where the binding of the virus to the angiotensin-converting enzyme 2 (ACE2) cell receptor occurs [1] . After cellular and viral membrane fusion, the viral genome replicates inside the cell. Viral RNAs activate the innate immune system, triggering signaling pathways leading to the expression of type I and III interferons (IFN-α/β and IFN-), proinflammatory cytokines, and chemokines, and the recruitment of inflammatory myeloid cells. Interferon-mediated signaling, in turn, upregulates the expression of multiple antiviral interferon-stimulated genes (ISGs) [1] . Mucosal immune response in the upper respiratory tract is crucial for the initial control of viral replication, the clearance of SARS-CoV-2, and the progression of the COVID-19 [1, 2] . A characteristic of SARS-CoV-2 infection is the high viral loads in the upper airways before symptom onset, which may be related to the reduced activation of some innate immunity pathways [3, 4] . Also, dysregulated antiviral immunity in the nasal epithelium seems to predict progression to severe COVID-19 [5, 6] . Therefore, differentiating protective immune response in the nasopharynx from that leading to fatal outcomes is essential in developing preventative and therapeutic strategies against We conducted a retrospective study of 255 SARS-CoV-2 infected patients from Hospital Biological samples (nasopharyngeal swabs) were obtained during the first 24 hours after the emergency admission. Samples were placed in a transport medium with guanidinium isothiocyanate (NEST Disposable Nasopharyngeal VTM Sampler kit, Wuxi NEST Biotechnology, Wuxi, China) for COVID-19 testing, and stored at -80ºC. This medium served as an inactivator and preservative for SARS-CoV-2 RNA and mucosal biomarkers mRNA. Viral RNA was obtained at the hospital from clinical samples using two automatic extractors: MagCore HF16 (RBC bioscience, Taipei, Taiwan) and ELITe Ingenius Supplementary Table 1 ). Samples were considered positive when all SARS-CoV-2 genes included in each RT-PCR assay were amplified. RNA previously extracted as above was reverse transcribed with the High-Capacity The primary endpoint during hospital admission was ICU admission or death within 28 days (ICU admission/death). A single episode was considered for each patient. When a patient was discharged from the emergency department and later readmitted during the study period, only the first hospital admission episode was considered for the analysis, and the corresponding respiratory sample for mucosal biomarkers. Also, we divided the study population in half into training and validation cohorts to evaluate the predictive value of the tested genes. A c c e p t e d M a n u s c r i p t Baseline characteristics of COVID-19 patients are shown in Supplementary Table 2 . Patients were 60% males, the median age was 63.8 years, and the main comorbidities were chronic heart disease, hypertension, chronic obstructive pulmonary disease, obesity, diabetes, and dyslipidemia. After hospital admission, 19.6% entered the ICU, 16.1% had invasive mechanical ventilation, and 14.1% died within 28 days. Moreover, healthy controls were 47.7% males, and the median age was 60 years. In adjusted regression models (Figure 2 ; the full description in Supplementary Table 3) , SARS-CoV-2 viral load was a risk factor (aOR=1.19, p-value<0.001), and CCL5 was a protective factor for ICU admission or death during hospital admission (aOR=0.70, p-value=0.002). When the whole cohort was divided in half (training and validation cohorts), we also found significant associations for SARS-CoV-2 and CCL5 viral load in both cohorts (p-value<0.05), supporting that the association between high levels of SARS-CoV-2 viral load and low levels of CCL5 expression with COVID-19 severity is robust. Moreover, CCL5 was the only one with an AUC> 0.70 (Supplementary Figure 3A) , and the combination with other mucosal biomarkers did not significantly improve the AUC value (data not shown). CCL5 was also directly correlated with higher peripheral oxygen saturation (SpO2) values at emergency admission (r=0.295; p<0.001) (Supplementary Figure 3B) . This study found that decreased expression of CCL5 and elevated SARS-CoV-2 viral load in nasopharyngeal samples were associated with poor COVID-19 outcomes. In our study, COVID-19 patients had upregulated innate immunity genes, which were directly associated with SARS-CoV-2 viral load. Characterizing the immune response triggered in the upper respiratory tract by SARS-CoV-2 is essential since the virus's infection, replication, and dissemination begins in this place. An adequate immune response in the nasopharynx contributes to controlling virus replication, preventing its spread towards the lower respiratory tract, and avoiding disease complications. Conversely, an unbalanced innate immune response is closely related to the COVID-19 severity and the risk of death [1] . We found that COVID-19 patients with high values of SARS-CoV-2 viral load had higher odds of ICU admission or death. In agreement with our data, some studies have found that SARS-CoV-2 viral loads on the upper respiratory tract are positively associated with disease severity [7] [8] [9] . However, others have found no correlation [4, 10, 11] . This difference may be related to different times between sample collection and SARS-CoV-2 viral load quantification. Moreover, higher levels of CCL5 were associated with better COVID-19 outcomes, and it was also the only biomarker with acceptable predictive performance. CCL5 (also known as RANTES) is a potent chemoattractant for several immune cells such as monocytes and NK cells and promotes interaction between T cells and dendritic cells, essential for virus control [12] . Thus, the CCL5 expression may help eliminate SARS-CoV-2 infection and prevent patients from developing severe COVID-19 [13] . In agreement with this, it has been described that in patients with critical COVID-19, CD8+ cytotoxic lymphocytes expressed lower levels of CCL5 [14] . Besides, COVID-19 patients with mild disease had higher nasopharyngeal CCL5 expression than those with severe pneumonia at the Not applicable. Abbreviations: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; ICU, intensive care unit; OR, odds ratio; aOR, adjusted odds ratio; 95%CI, 95% confidence interval; p-value, level of significance; CCL5, Chemokine (C-C motif) ligand 5; VL, viral load. Characteristics of SARS-CoV-2 and COVID-19 The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection Upper airway gene expression reveals suppressed immune responses to SARS-CoV-2 compared with other respiratory viruses A diagnostic host response biosignature for COVID-19 from RNA profiling of nasal swabs and blood Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19 Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 Upper Respiratory Tract Viral Ribonucleic Acid Load at Hospital Admission Is Associated With Coronavirus Disease 2019 Disease Severity Association Between Upper Respiratory Tract Viral Load, Comorbidities, Disease Severity, and Outcome of Patients With SARS-CoV-2 Infection SARS-CoV-2 viral load at presentation to hospital is independently associated with the risk of death Upper Respiratory Tract Levels of Severe Acute Respiratory Syndrome Coronavirus 2 RNA and Duration of Viral RNA Shedding Do Not Differ Between Patients With Mild and Severe/Critical Coronavirus Disease Viral genomic, metagenomic and human transcriptomic characterization and prediction of the clinical forms of COVID-19 Chemokines and chemokine receptors: positioning cells for host defense and immunity Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis The datasets used and analyzed during the current study are available from the corresponding authors upon reasoned request. We want to acknowledge the patients in this study for their participation. This study would not have been possible without the collaboration of all medical and nursing staff and data managers who have taken part in the project.